Literature DB >> 33227372

Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia.

T S Usenko1, A I Bezrukova2, D A Bogdanova2, A E Kopytova2, K A Senkevich3, E V Gracheva4, A A Timofeeva5, I V Miliukhina6, E Y Zakharova7, A K Emelyanov3, S N Pchelina8.   

Abstract

Lysosomal integral membrane protein-2 (LIMP-2), encoded by the SCARB2 gene, is the specific lysosomal receptor for glucocerebrosidase enzyme. Association between rs6812193 and rs68250047 of SCARB2 with PD has been shown in genetic studies, including large genome-wide association studies. The aim of the current study was to determine whether rs6812193 and rs8475 are associated with PD in Russia. rs6812193 and rs8475 were genotyped in a total of 604 PD patients (65 PD patients with positive (fPD) and 539 PD patients with negative family history (sPD)) and 413 controls and also in 17 patients with PD associated with GBA mutations (PD-GBA) and 18 asymptomatic GBA mutation carriers (GBA-Carriers). SCARB2 expression was measured by real-time PCR in CD45+ blood cells in part of individuals in the studied groups. No linkage disequilibrium was shown between rs6812193 and rs8475 in Russian population. Increased PD risk for TT variant of rs8475 (OR = 2.02; p < 0.001) was found in sPD patients but not in fPD. rs6812193 and rs8475 were not associated with age at onset (AAO) of PD. SCARB2 expression level was decreased in GBA-PD patients and GBA-Carriers compared to PD patients (padjusted = 0.02, padjusted = 0.003, respectively) and GBA-Carriers compared to controls (padjusted = 0.013) with no significant difference in PD patients and controls. SCARB2 expression was not modified with rs6812193 and rs8475. In conclusion, rs8475 was associated with PD status. rs6812193 and rs8475 are not genetic modifier of AAO of PD and do not influence on SCARB2 mRNA level in CD45+ blood cells in studied groups. SCARB2 expression could be modified with GBA mutations and is independent of PD status.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GBA; Parkinson’s disease; SCARB2; ge at onset; risk; rs6812193; rs8475

Mesh:

Substances:

Year:  2020        PMID: 33227372     DOI: 10.1016/j.neulet.2020.135509

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Relationship between polymorphism of receptor SCARB2 gene and clinical severity of enterovirus-71 associated hand-foot-mouth disease.

Authors:  Xia Wang; Hong Liu; Ying Li; Rui Su; Yamin Liu; Kunyan Qiao
Journal:  Virol J       Date:  2021-06-30       Impact factor: 4.099

Review 2.  Ceramide Metabolism and Parkinson's Disease-Therapeutic Targets.

Authors:  Antía Custodia; Marta Aramburu-Núñez; Clara Correa-Paz; Adrián Posado-Fernández; Ana Gómez-Larrauri; José Castillo; Antonio Gómez-Muñoz; Tomás Sobrino; Alberto Ouro
Journal:  Biomolecules       Date:  2021-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.